Fort Washington Investment Advisors 13F: Cuts AMGN Stake by $38M
Fort Washington has reduced its position in Amgen Inc. as of its latest filing.
Reviewed by automated data checks against the source filing. How we make and check alerts
Fort Washington Investment Advisors sold 90,613 shares from its stake in Amgen Inc. ($AMGN), a 98.91% decrease, according to a 13F filing with the SEC dated October 15, 2026. It reported 995 shares worth $419,402 at the end of the quarter.
Since the filing, $AMGN is down 0.3% to date (from the $434.03 close on Oct 15, 2026).
Find the original: Fort Washington Investment Advisors 13F filings on SEC EDGAR
AMGN
Amgen Inc.
Key Points
- Fort Washington Investment Advisors cut its stake in Amgen Inc. by 90,613 shares, leaving it with just 995 shares worth approximately $419,402 as of October 15, 2026.
- The stock recently traded around $432.06, which is 4.2% above its 50-day moving average and 17.3% above its 200-day average.
- Analysts have maintained price targets for Amgen, with a consensus target mean of $394.98, suggesting that recent price levels are above this target by about 9.4%.
Get $AMGN trade alerts by text
We text you when insiders, Congress or big funds trade $AMGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Amgen Inc. alert may contain errors. Disclosures
Fort Washington Investment Advisors has cut its stake in Amgen Inc. (AMGN) by 90,613 shares, according to its latest Form 13F filing with the SEC on October 15, 2026. This reduction brings the firm's total to just 995 shares valued at approximately $419,402. This adjustment represents a substantial decrease of about 98.9% in their holdings.
Fort Washington Investment Advisors vs. the S&P 500
Hypothetical returns from Fort Washington Investment Advisors's disclosed trades, not real profit or advice. How we model this.
What Changed in Fort Washington Investment Advisors' Amgen Position
Fort Washington reduced its position in Amgen Inc., going from 91,608 shares to 995 shares. The significant cut reduces exposure to the biopharmaceutical company as the fund reassesses its investment strategy.
Other Institutional Activity in Amgen
Several other major institutional investors have also updated their positions in Amgen recently. Blackrock Inc. grew its holdings by 2,260,856 shares, ending with 49,362,016 shares worth about $21.3 billion. Vanguard Capital Management LLC added 234,604 shares, bringing its total to 35,250,101 shares valued at roughly $15.2 billion. State Street Corporation held steady, with no change, while Capital World Investors trimmed its position by 213,811 shares, resulting in 29,075,329 shares worth about $12.6 billion. Invesco Ltd. increased its stake by 435,254 shares, totaling 16,320,446 shares with a value of approximately $7.1 billion.
Amgen Inc. Stock Up 1.4%
Amgen's stock recently traded around $432.06 as of October 16, 2026. This price is notable because it is above both the 50-day and 200-day moving averages, by 4.2% and 17.3%, respectively. However, the stock is still about 3.3% below its 52-week high of $447.03, indicating some room for growth if it can regain previous highs.
Recent Earnings
Amgen reported trailing twelve-month revenue of approximately $38.1 billion, with a net margin of 23.0% and return on equity at 91.5%. The company is due to report its next earnings on November 3, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 6.1%. Revenue missed estimates by 1.5%.
-
Profit surprise
EBITDA missed by 45 percent. Operating income missed by 28 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
1 target raise, 2 target cuts.
-
Earnings quality
Gross margin up 4.6 points. Operating margin up 16.5 points. Positive free cash flow.
Earnings Call Summary
Amgen had a strong first quarter with earnings per share of 5.15 dollars beating expectations of 4.73 dollars. Six key medicines grew sales by 24 percent year over year and now make up 70 percent of total sales. The obesity drug Meritide is advancing well in late-stage testing with new studies showing better tolerance when patients take it less frequently, potentially every eight to twelve weeks instead of weekly injections.
Guidance Amgen raised its 2026 outlook to revenue between 37.1 billion and 38.5 billion dollars, and earnings per share between 21.70 and 23.10 dollars. The company expects its fast-growing medicines like Repatha and Evenity to offset patent losses. Management said capital spending will remain at about 2.6 billion dollars to scale manufacturing for new drug launches.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Insider Buying and Selling at Amgen Inc.
Recent insider selling includes several officers at Amgen. On August 6, 2026, Officer Nancy A Grygiel sold 2,970 shares at an average price of $402.16, totaling about $1.19 million. Another officer, Derek Miller, sold 3,890 shares at an average price of $402.54, amounting to about $1.57 million. Officer Rachna Khosla sold 3,252 shares, valued at roughly $1.35 million, on August 13, 2026.
Analysts Set New Price Targets
Analysts have been maintaining their ratings for Amgen amidst these changes. On October 8, 2026, RBC Capital maintained its rating at Outperform with a price target of $430. On October 9, UBS also maintained its Buy rating, raising its target from $430 to $470. BMO Capital and Wells Fargo have maintained ratings of Market Perform and Equal-Weight, respectively, with targets at $415 and $430. Lastly, Guggenheim maintained a Neutral rating with a target of $378.
About Amgen
Amgen Inc. is a leading biopharmaceutical company that discovers, develops, and manufactures drugs for various therapeutic areas. The recent cut by Fort Washington reflects ongoing adjustments in institutional strategies and market conditions as the healthcare sector evolves.
Bottom Line
Investors should keep an eye on Amgen's upcoming earnings announcement on November 3, 2026, as well as any further institutional filings. The recent changes in holdings by significant investors might signal shifts in market sentiment, even as the company's fundamentals remain strong. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.
Related Filing Alerts
Source: Fort Washington Investment Advisors's 13F filing on $AMGN (Oct 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Fort Washington Investment Advisors 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts